Foghorn Therapeutics reported steady progress across its chromatin-targeting pipeline, keeping its SMARCA2 inhibitor FHD-909 on track in a Phase 1 dose-escalation study for SMARCA4-mutated cancers with non-small cell lung cancer as the primary focus. The company advanced three first-in-class selective degrader programs: a CBP degrader that entered non-GLP toxicology with IND-readiness targeted for 2026; a selective EP300 degrader showing robust preclinical activity in hematologic malignancies, with IND-enabling work expected in 2026; and an ARID1B degrader moving toward in vivo proof of concept in 2026. Backed by $180.3 million in cash and equivalents as of September 30, 2025, Foghorn guided to a runway into 2028 and announced the planned departure of its chief financial officer. A strategic collaboration with Lilly continues to anchor the SMARCA2 franchise, including a 50/50 U.S. co-development and co-commercialization construct.
The strategic question is whether targeted synthetic lethality—delivered through selective inhibition or degradation of chromatin remodelers—can move from biomarker-enriched niches into frontline standards, especially in NSCLC, where SMARCA4 mutations approach double-digit incidence. If the early safety and efficacy profile of FHD-909 supports combinations with PD-1 blockade and KRAS inhibitors, the program could slot into existing treatment paradigms rather than relying on monotherapy uptake. That path would demand tight alignment across biomarker testing, companion diagnostic readiness, and payer evidence that the additive benefit justifies the combination costs.
For Commercial leaders, the stakes span segmentation and access. SMARCA4-mutant NSCLC is large enough to matter but still requires disciplined test adoption in both academic and community settings. Real-world data will be critical for demonstrating detection rates, treatment patterns, and outcomes outside trial networks. The Lilly partnership signals intent to scale, but U.S. co-commercialization also raises the bar on launch execution, price-value narratives for combinations, and coordination on CDx strategies. Medical Affairs teams will need to educate oncologists on a new mechanism within the BAF complex, position synthetic lethality alongside immuno-oncology, and generate RWE that de-risks payer decisions for combo regimens.
On the degrader front, Foghorn is betting that selectivity can solve the toxicity limits seen with dual CBP/EP300 approaches. If the CBP degrader can avoid hematologic liabilities, it may unlock ep300-mutant solid tumors and CBP-dependent settings like ER+ breast cancer, with the added commercial wrinkle of a long-acting injectable formulation that could improve adherence and clinic flow. The EP300 degrader’s preclinical breadth in multiple myeloma and diffuse large B-cell lymphoma, including activity in IMiD-resistant lines and a cleaner thrombocytopenia profile, positions it for combination-heavy development. Competitively, this places Foghorn in the vanguard of the protein degradation “wave two,” where sponsors pursue epigenetic targets, diversify E3 ligases, and optimize modalities—forging a path distinct from first-generation CRBN-centric assets.
The ARID1B degrader extends the synthetic lethality thesis toward a tumor-agnostic opportunity tied to ARID1A mutations across up to 5% of solid tumors. Success here would reinforce a broader industry pivot toward functionally defined dependencies rather than single oncogene addiction, with basket trial designs and pan-tumor access implications. With multiple INDs converging in 2026 and a lengthy cash runway, the near-term readouts that matter are FHD-909 safety, early combination tolerability, and CDx clarity. The forward test for the field is whether chromatin-directed degraders can demonstrate enough incremental benefit in combination settings to win payer support and displace entrenched regimens—or whether they will remain precision tools for the few rather than the new backbone for the many.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
